4d Pharma Plc Share Price | |
---|---|
Price | 33.10 |
Bid | 32.50 |
Ask | 33.40 |
Change | -0.90 (-2.65%) |
Volume | 750,824 |
Open | 33.15 |
High | 33.45 |
Low | 32.35 |
Prev. Close | 33.10 |
Currency | GBX |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 180m |
Market Capitalisation | £60m |
Market Size | 10,000 |
52 Week High | 109.00 |
52 Week High Date | 17-Jun-2021 |
52 Week Low | 24.50 |
52 Week Low Date | 07-Mar-2022 |
# Trades | 111 |
---|---|
Vol. Sold | 389,011 |
Sold Value | £128,279.03 |
Vol. Bought | 284,988 |
Bought Value | £94,559.47 |
PE Ratio | -1.040 |
Earnings | -31.83 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
19-May-22 | 16:35:09 | 33.10 | 2,422 | Sell* | 32.50 | 33.40 | 801.68 | UT Uncrossing Trade |
19-May-22 | 16:29:52 | 32.70 | 133 | Sell* | 32.70 | 33.40 | 43.49 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.70 | 193 | Sell* | 32.70 | 33.40 | 63.11 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.70 | 352 | Sell* | 32.70 | 33.40 | 115.10 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.70 | 185 | Sell* | 32.70 | 33.40 | 60.50 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.70 | 303 | Sell* | 32.70 | 33.40 | 99.08 | A Automatic Execution |
19-May-22 | 16:29:52 | 33.40 | 352 | Buy* | 32.70 | 33.40 | 117.57 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.75 | 807 | Sell* | 32.75 | 33.45 | 264.29 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.75 | 523 | Sell* | 32.75 | 33.45 | 171.28 | A Automatic Execution |
19-May-22 | 16:29:52 | 32.75 | 494 | Sell* | 32.75 | 33.45 | 161.79 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
31-Dec-21 | 31-Dec-21 | Notification of Holding | Alexander James Stevenson held the position of Chief Scientific Officer at the time of this trade. Alexander James Stevenson | 0.00 | 0 | 9,358,464 | |
31-Dec-21 | 31-Dec-21 | Notification of Holding | Duncan Joseph Peyton held the position of CEO at the time of this trade. Duncan Joseph Peyton | 0.00 | 0 | 9,514,771 | |
16-Apr-21 | 15-Apr-21 | Placing | Alexander James Stevenson held the position of Chief Scientific Officer at the time of this trade. Alexander James Stevenson | 110.00 | GBX | 658,840 | 8,976,736 |
16-Apr-21 | 15-Apr-21 | Placing | Duncan Joseph Peyton held the position of CEO at the time of this trade. Duncan Joseph Peyton | 110.00 | GBX | 658,840 | 9,018,675 |
29-Dec-20 | 29-Dec-20 | Notification of Holding | David Robert Norwood held the position of Non-Executive Director at the time of this trade. David Robert Norwood | 0.00 | 0 | 3,900,000 |